Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy

Author(s): Hitoshi Yoshiji, Shigeki Kuriyama, Ryuichi Noguchi, Hiroshi Fukui.

Journal Name: Current Cancer Drug Targets

Volume 4 , Issue 7 , 2004

Become EABM
Become Reviewer

Abstract:

Angiotensin-I converting enzyme inhibitors (ACE-Is) are commonly used as safe antihypertensive agents, and it has recently been suggested that they decrease the risk of cancer development. Recent studies have revealed that the renin-angiotensin system (RAS) is involved in the development of many types of tumor. Angiotensin-II (AT-II) has many biological effects, including neo-vascularization, which plays a pivotal role in tumor development. AT-II induces a potent angiogenic factor, namely the vascular endothelial growth factor (VEGF). Some studies have proven that several ACE-Is are potent inhibitors of experimental tumor development and angiogenesis at clinically comparable doses. VEGF expression in tumors is also significantly suppressed by ACE-Is. When used in combination with the conventional anti-cancer drugs, ACEIs exert more potent anti-tumor activities as compared with either single agent, in addition to suppression of the intra-tumoral angiogenesis. Furthermore, ACE-Is reportedly not only suppress tumor growth but also attenuate the carcinogenesis process in which angiogenesis is involved. Since ACE-Is are already in widespread clinical use without any serious adverse effects, they may represent a potential new strategy for cancer therapy and chemoprevention.

Keywords: angiotensin-II, ace inhibitor, angiogenesis, cancer, renin-angiotensin system

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 4
ISSUE: 7
Year: 2004
Page: [555 - 567]
Pages: 13
DOI: 10.2174/1568009043332790
Price: $58

Article Metrics

PDF: 6